Bradley Rowens, MD
Pulmonary Disease · Novi, MINPI 1306846431
Payments from drug & device makers
Across 94 payments — averaging $280.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$25K
- Axsome Therapeutics, Inc.$359
- Harmony Biosciences LLC$349
- Inspire Medical Systems, Inc.$156
- Boehringer Ingelheim$116
- Resmed Corp$96
- plus $86 from 3 others
What the payments were for
- Speaking & faculty fees$22,60086%
- Travel & lodging$1,2805%
- Food & beverage$2,3319%
- Education$1571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 49 | $25,206 |
| Axsome Therapeutics, Inc. | 9 | $359 |
| Harmony Biosciences LLC | 23 | $349 |
| Inspire Medical Systems, Inc. | 4 | $156 |
| Boehringer Ingelheim | 1 | $116 |
| Resmed Corp | 4 | $96 |
| 3b Medical, Inc. | 2 | $53 |
| Itamar Medical Inc | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,369 in reported general payments places this provider in the 85th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $154,409 |
| Modafinil | 42 | $5,011 |
| Trazodone Hcl | 108 | $1,130 |
| Armodafinil | 27 | $1,008 |
| Eszopiclone | 61 | $743 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 17 | $735 |
| Doxepin Hcl | 16 | $581 |
| Zolpidem Tartrate | 49 | $564 |
| Gabapentin | 33 | $486 |
| Triazolam | 13 | $273 |
| Temazepam | 26 | $238 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $206 |
| Clonazepam | 43 | $174 |
| Alprazolam | 24 | $16 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Novi
- Philip KaplanNovi$35K
- Njira LugogoAnn Arbor$12.9M
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Gary FergusonLivonia$1.5M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Irina ShanidzeFarmington Hills$1.2M
- Oscar Parodi Ortiz de VillateWarren$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.